share_log

Investors Shouldn't Be Too Comfortable With Henan Taloph Pharmaceutical StockLtd's (SHSE:600222) Earnings

Investors Shouldn't Be Too Comfortable With Henan Taloph Pharmaceutical StockLtd's (SHSE:600222) Earnings

投資者不應該對河南塔洛夫製藥股票有限公司(上海證券交易所代碼:600222)的收益過於滿意
Simply Wall St ·  04/03 19:26

Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the details.

河南塔洛夫製藥股份有限公司, Ltd(上海證券交易所股票代碼:600222)強勁的收益報告未能推動其股票的市場。我們進行了一些挖掘,在細節中發現了一些相關的因素。

earnings-and-revenue-history
SHSE:600222 Earnings and Revenue History April 3rd 2024
SHSE: 600222 2024 年 4 月 3 日的收益和收入歷史記錄

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

For anyone who wants to understand Henan Taloph Pharmaceutical StockLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥8.4m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. If Henan Taloph Pharmaceutical StockLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

對於任何想了解河南塔洛夫製藥股份有限公司在法定數字之外的利潤的人來說,值得注意的是,在過去的十二個月中,從價值840萬元人民幣的不尋常物品中獲得了法定利潤。雖然獲得更高的利潤總是件好事,但來自不尋常物品的巨額捐款有時會抑制我們的熱情。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。這正如你所預料的那樣,因爲這些增強被描述爲 “不尋常”。如果河南塔洛夫製藥股份有限公司認爲這種捐款不會重演,那麼在其他條件相同的情況下,我們預計其本年度的利潤將下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Henan Taloph Pharmaceutical StockLtd.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對河南塔洛夫製藥股份有限公司的資產負債表分析

Our Take On Henan Taloph Pharmaceutical StockLtd's Profit Performance

我們對河南塔洛夫製藥股份有限公司盈利表現的看法

We'd posit that Henan Taloph Pharmaceutical StockLtd's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Henan Taloph Pharmaceutical StockLtd's statutory profits are better than its underlying earnings power. The good news is that it earned a profit in the last twelve months, despite its previous loss. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. In terms of investment risks, we've identified 1 warning sign with Henan Taloph Pharmaceutical StockLtd, and understanding it should be part of your investment process.

我們認爲,河南塔洛夫製藥股份有限公司的法定收益並不能完全反映當前的生產率,這是因爲這個很大的不尋常項目。因此,我們認爲河南塔洛夫製藥股份有限公司的法定利潤可能好於其基礎盈利能力。好消息是,儘管之前出現虧損,但它在過去十二個月中還是實現了盈利。當然,我們只是在分析其收益時才浮出水面;人們還可以考慮利潤率、預測增長和投資回報率等因素。請記住,在分析股票時,值得注意所涉及的風險。在投資風險方面,我們已經向河南塔洛夫製藥股份有限公司確定了一個警告信號,我們知道這應該是您投資過程的一部分。

Today we've zoomed in on a single data point to better understand the nature of Henan Taloph Pharmaceutical StockLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了單一數據點,以更好地了解河南塔洛夫製藥股份有限公司利潤的性質。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論